Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Janney Montgomery Scott restated a “buy” rating and set a $25.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Jefferies Group LLC restated a “buy” rating and set a $22.00 price objective (down previously from $24.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 11th. Needham & Company LLC reduced their price objective on Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, May 11th. Finally, ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $21.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 0.44% during mid-day trading on Friday, hitting $11.37. The company’s stock had a trading volume of 303,268 shares. The company’s market cap is $334.94 million. The company has a 50-day moving average of $12.18 and a 200 day moving average of $12.12. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.55.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.19. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $3.55 million. On average, analysts expect that Collegium Pharmaceutical will post ($3.14) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/07/collegium-pharmaceutical-inc-coll-stock-rating-lowered-by-bidaskclub.html.

In other news, insider Paul Brannelly acquired 10,000 shares of Collegium Pharmaceutical stock in a transaction dated Friday, May 12th. The stock was bought at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the completion of the acquisition, the insider now directly owns 110,227 shares in the company, valued at approximately $1,011,883.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 25.76% of the company’s stock.

Several large investors have recently modified their holdings of COLL. American International Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $127,000. Credit Suisse AG boosted its stake in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares in the last quarter. Institutional investors own 82.27% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.